Not applicableEnded earlyNCT01425294What this trial is testingCollection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentWho this might be right forBreast Cancer AstraZeneca 231
Early research (Phase 1)Ended earlyNCT07214662What this trial is testingEvaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT03202862What this trial is testingThe Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerWho this might be right forBreast Neoplasms Fudan University 50
Not applicableUnknownNCT03430024What this trial is testingNuclear Myosin VI - a Therapeutic Target in Breast CancerWho this might be right forBreast Cancer Maidstone & Tunbridge Wells NHS Trust 120
Testing effectiveness (Phase 2)Study completedNCT01625286What this trial is testingInvestigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer PatientsWho this might be right forAdvanced or Metastatic Breast CancerER+ve Advanced or Metastatic Breast Cancer AstraZeneca 148
Large-scale testing (Phase 3)Study completedNCT00963729What this trial is testingChemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By SurgeryWho this might be right forBreast Cancer Imperial College London 756
Testing effectiveness (Phase 2)UnknownNCT00931450What this trial is testingSunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast CancerWho this might be right forBreast Cancer Institut Català d'Oncologia 70
Not applicableWithdrawnNCT03266562What this trial is testingEstrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission MammographyWho this might be right forBreast Neoplasm Mayo Clinic
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07410559What this trial is testingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast CancerWho this might be right forBreast Cancer Fudan University 189
Testing effectiveness (Phase 2)Looking for participantsNCT06500208What this trial is testingNeoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BCWho this might be right forBreast Cancer Shanghai Jiao Tong University School of Medicine 48
Not applicableStudy completedNCT01385280What this trial is testingPilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast CancerWho this might be right forEstrogen Receptor-positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Cancer+2 more University of Arizona 13
Testing effectiveness (Phase 2)Ended earlyNCT01823835What this trial is testingGDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 152
Testing effectiveness (Phase 2)Ended earlyNCT00892268What this trial is testingAcupuncture or Medication in Reducing Pain in Postmenopausal Women With Breast Cancer and Joint PainWho this might be right forBreast CancerMenopausal SymptomsPain University of Arizona 68
Testing effectiveness (Phase 2)Looking for participantsNCT07222215What this trial is testingPhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Who this might be right forEstrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more Kristina A. Fanucci 297
Early research (Phase 1)UnknownNCT05957939What this trial is testingTargeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical TrialWho this might be right forTNBC - Triple-Negative Breast Cancer Ministry of Health, Saudi Arabia 2
Testing effectiveness (Phase 2)Ended earlyNCT02457910What this trial is testingTaselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast CancerWho this might be right forEstrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more Vanderbilt-Ingram Cancer Center 30
Not applicableStudy completedNCT02057029What this trial is testingAssessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast CancerWho this might be right forBreast CancerEarly Stage Estrogen Receptor (ER) Positive Breast Cancer Yale University 96
Testing effectiveness (Phase 2)Study completedNCT02069093What this trial is testingOpen-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Novartis Pharmaceuticals 92
Very early researchStudy completedNCT03962647What this trial is testingA 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast CancerWho this might be right forEstrogen Receptor-positive Breast Cancer Vanderbilt-Ingram Cancer Center 31
Not applicableLooking for participantsNCT06401889What this trial is testingEnhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor TherapyWho this might be right forAnatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8+4 more Mayo Clinic 35